The pivotal phase III KEYNOTE-426 trial investigating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Inlyta (axitinib), Pfizer’s tyrosine kinase inhibitor, met both primary endpoints of overall survival and progression-free survival in the first-line treatment of advanced or metastatic renal cell carcinoma.
Elizabeth Comen originally set out to write a book about the wellness industry, but ended up writing a different book altogether.
